What Is PT-141?

PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin-4 receptors (MC4R) in the central nervous system . It was developed from the melanocyte-stimulating hormone analog Melanotan II and is FDA-approved under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women .

Because PT-141 has been through multiple phases of human clinical trials, we have better safety data for this peptide than for many others used in clinical practice. This guide draws primarily from that clinical trial data rather than from animal studies or anecdotal reports. For an overview of what PT-141 can do, see our PT-141 benefits guide.

Common Side Effects from Clinical Trials

The following side effects were identified during the RECONNECT Phase 3 clinical trials, which involved over 1,200 premenopausal women :

Nausea

Nausea is the most frequently reported side effect of PT-141, occurring in approximately 40% of patients in clinical trials . The nausea is typically mild to moderate and tends to begin within an hour of injection. For most users, it resolves within a few hours and often diminishes with repeated use as the body adjusts to the medication.

Some strategies that may help manage nausea include:

• Eating a light meal before administration
• Staying hydrated
• Starting with a lower dose and titrating up as tolerated
• Taking an anti-nausea medication as recommended by your physician

Flushing

Flushing, a warm or reddened feeling in the face and upper body, was reported by approximately 20% of trial participants . This occurs because melanocortin receptor activation can affect vascular tone. The flushing is temporary and typically resolves within a few hours.

Injection Site Reactions

As with any injectable medication, some users experience reactions at the injection site. These may include mild redness, bruising, itching, or tenderness. Proper injection technique and rotating injection sites can help minimize these effects. For detailed injection guidance, see our PT-141 how to inject guide.

Headache

Headaches were reported by approximately 11% of participants in clinical trials . These are generally mild and resolve without intervention. Over-the-counter pain relief may be used if needed, following your physician's guidance.

Cardiovascular Considerations

PT-141 can cause transient increases in blood pressure. In clinical trials, the average increase was approximately 2 to 3 mmHg in systolic blood pressure, with effects resolving within 12 hours of dosing .

While this increase is modest for most people, it has important implications for certain populations:

• Uncontrolled hypertension: PT-141 is not recommended for individuals with uncontrolled high blood pressure .
• Cardiovascular disease: Those with significant cardiovascular conditions should discuss the risks with their physician before using PT-141.
• Blood pressure monitoring: Your physician may recommend monitoring blood pressure during initial use to establish your individual response.

A decrease in heart rate has also been observed in some patients. This is generally not clinically significant but should be evaluated in the context of your overall cardiovascular health.

Skin Hyperpigmentation

Because PT-141 is derived from Melanotan II, which was originally studied for its tanning effects, there is a theoretical concern about skin darkening. In clinical trials, focal areas of hyperpigmentation were reported in some patients, particularly on the face, gums, and breasts .

These pigmentation changes were generally mild and, in most cases, resolved after discontinuation. However, this is a side effect that should be discussed with your physician, especially if you have a history of skin conditions or are concerned about changes in skin appearance.

Less Common Side Effects

The following were reported less frequently in clinical trials but are worth noting:

• Fatigue or drowsiness
• Nasal congestion
• Dizziness
• Cough
• Abdominal discomfort
• Tingling or numbness at the injection site

If you experience any side effect that is persistent, severe, or concerning, contact your physician promptly.

Who Should Not Use PT-141

Based on clinical trial data and FDA labeling, PT-141 should not be used by:

• Individuals with uncontrolled hypertension or significant cardiovascular disease
• Pregnant or breastfeeding women (PT-141 has not been studied in pregnancy, and potential risks to the fetus are unknown)
• Individuals currently taking medications that affect blood pressure, unless cleared by their physician
• Anyone with a known hypersensitivity to bremelanotide or any component of the formulation

Drug Interactions

PT-141 should be used with caution alongside other medications. Key interaction considerations include:

• Naltrexone: PT-141 should not be used by patients taking naltrexone or other opioid receptor antagonists, as it may decrease the efficacy of naltrexone .
• Antihypertensives: Because PT-141 can affect blood pressure, coordination with blood pressure medications may be necessary.
• Oral medications: PT-141 may slow gastric emptying, which could delay the absorption of oral medications taken around the same time. A separation of at least one hour is generally recommended.

Always provide your physician with a complete list of your current medications before starting PT-141.

Long-Term Safety

The Phase 3 clinical trials for PT-141 included an open-label extension phase lasting up to 52 weeks, providing some longer-term safety data . During this period, no new safety signals emerged, and the side effect profile remained consistent with shorter-term use.

However, data beyond one year of use is limited, and ongoing monitoring by a physician is recommended for anyone using PT-141 over extended periods.

Safety and Side Effects Summary

Compared to many peptides used in clinical practice, PT-141 has a well-characterized safety profile supported by human clinical trial data. The most important points to remember:

• Nausea is common but usually manageable and often improves over time
• Blood pressure effects are generally mild but warrant attention in at-risk individuals
• Skin pigmentation changes are possible and should be monitored
• Physician supervision ensures appropriate patient selection and monitoring

How Form Blends Can Help

Understanding side effects is an important part of making informed decisions about any therapy. At Form Blends, our physician-supervised telehealth platform provides:

• A comprehensive medical evaluation before prescribing PT-141
• Screening for cardiovascular risk factors and potential drug interactions
• Pharmaceutical-grade PT-141 from licensed pharmacies
• Personalized dosing guidance to minimize side effects
• Ongoing monitoring and physician access throughout your treatment

Our physicians take safety seriously. If PT-141 is not the right fit for your health profile, they will tell you directly and explore alternatives.

Frequently Asked Questions

Does PT-141 nausea go away?

For most users, nausea diminishes with repeated use as the body adjusts. Eating a light meal before injection and staying hydrated can also help. If nausea is severe or persistent, your physician may adjust your dose or recommend an anti-nausea strategy.

Can PT-141 affect blood pressure?

Yes. PT-141 can cause transient increases in blood pressure, typically modest (2 to 3 mmHg systolic). This effect resolves within about 12 hours. PT-141 is not recommended for individuals with uncontrolled hypertension. Your physician will evaluate your cardiovascular health before prescribing.

Will PT-141 darken my skin?

Some clinical trial participants experienced mild focal hyperpigmentation, particularly on the face, gums, or breasts. This is related to PT-141's melanocortin receptor activity. Changes were generally reversible after stopping the medication. Discuss any pigmentation concerns with your physician.

How long do PT-141 side effects last?

Most side effects, including nausea and flushing, resolve within a few hours of administration. Blood pressure effects typically normalize within 12 hours. If side effects persist beyond 24 hours, contact your physician.

Is PT-141 safe to use with other medications?

PT-141 has known interactions with naltrexone and may interact with blood pressure medications and oral drugs (due to effects on gastric emptying). Always share your complete medication list with your physician before starting PT-141.